Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cetuximab and Cemiplimab in HNSCC
NCT06855212Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2025
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab and KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Moffitt Cancer Center. Primary endpoint: Major and Complete Pathologic Response Rate. Started Feb 2025; status: active, not recruiting.
02
Drugs
cemiplimabKL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06855212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855212.